|
Mark Torii is president of SPKK, the company's country operation in Japan, and he is responsible for leading business operations there. Japan is the second largest pharmaceutical market in the world, after the U.S. market.
Torii joined Schering-Plough Corporation in 1995. Under his leadership, several important new drugs have been launched, including REBETOL and PEG-INTRON for the treatment of chronic hepatitis C; CLARITIN Redi-Tabs for the treatment of allergies; and other key products have been submitted for regulatory review, including TEMODAR, submitted for the treatment of certain types of brain tumors; and ZETIA, submitted for the treatment of high cholesterol.
Prior to joining Schering-Plough, Torii served as president and representative director of Rhone-Poulenc Rorer, Japan and managing director of sales & marketing for Nippon Roche, Japan. He has also held positions at Hoffmann-La Roche in Basel, Switzerland and the United States.
Torii received a B.A. degree from Loyola College, Baltimore, Md., and an M.B.A. from Sophia University, Tokyo. He also has participated in advanced management programs at Harvard Business School, Cambridge, Mass. | 